Shots: Regeneron is presenting results from studies evaluating Libtayo in indications NSCLC (P-I), CSCC(P-I), HCC(P-I), BCC (P-II), R/M Cervical Cancer (P-I), Libtayo + RT+ GM-CSF for R/M HNSCC (P-I) Libtayo is a mAb targeting the immune checkpoint receptor PD-1 and was recently approved by the US FDA to treat locally advanced CSCC or mCSCC In […]Read More
Tags : mCSCC
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US